Valuation: GlaxoSmithKline Pakistan Limited

Market Cap 123B 443M 387M 356M 332M 630M 42.2B 639M 4.28B 1.66B 20.75B 1.66B 1.63B 71.49B P/E 2026 *
11.2x
P/E 2027 * 9.58x
Enterprise Value 123B 443M 387M 356M 332M 630M 42.2B 639M 4.28B 1.66B 20.75B 1.66B 1.63B 71.49B EV / Sales 2026 *
1.79x
EV / Sales 2027 * 1.62x
Free-Float
16.89%
Yield 2026 *
4.8%
Yield 2027 * 5.38%
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Chief Financial Officer, Effective June 30, 2026 CI
08/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Hasham Baber as Executive Director of the Board of Directors, Effective June 30, 2026 CI
01/06 GlaxoSmithKline Pakistan Limited Announces Resignation of Ana Paula De Freitas Passos as Non-Executive Director, Effective May 31, 2026 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Final Cash Dividend for the Year Ended 31 December, 2025 CI
30/04 GlaxoSmithkline Pakistan Limited Approves Board Elections, Effective May 25, 2026 CI
27/04 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
09/04 GlaxoSmithKline Pakistan Limited Proposes Final Cash Dividend for the Financial Year Ended 31 December 2025 CI
07/04 GlaxoSmithKline Pakistan Limited Announces Board Changes CI
31/03 GlaxoSmithKline Pakistan Limited Announces Resignation of Lai Kuen Goh as Chairperson and Non-Executive Director, with Effect from March 31, 2026 CI
26/03 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25/10/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
02/09/25 GlaxoSmithKline Pakistan Limited Declares Interim Cash Dividend for the Half Year Ended June 30, 2025 CI
26/08/25 GlaxoSmithKline Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+2.66%
1 week+5.48%
Current month+4.53%
1 month+10.58%
3 months+18.81%
6 months-5.68%
Current year-0.71%
1 week 363
Extreme 363
393
1 month 344.01
Extreme 344.01
393
Current year 293.09
Extreme 293.09
459.27
1 year 293.09
Extreme 293.09
459.94
3 years 68
Extreme 68
481
5 years 68
Extreme 68
481
10 years 68
Extreme 68
481
Manager TitleAgeSince
Chief Executive Officer - 01/03/2020
Director of Finance/CFO - 01/06/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 07/05/2011
Director/Board Member - 05/12/2018
Director/Board Member 72 02/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.66%+5.48%-1.00%+413.48% 432M
+3.45%+7.65%+55.77%+158.84% 1,082B
-1.16%+7.42%+69.09%+58.92% 633B
-0.77%+7.37%+36.87%+93.77% 461B
-0.35%+1.85%+31.30%+24.86% 339B
-0.56%+1.17%+41.96%+39.64% 301B
-0.08%+1.49%+32.40%+44.75% 292B
-1.54%+2.58%-25.52%-39.75% 225B
+3.55%+6.05%+26.04%+68.52% 202B
+0.40%+6.00%+17.72%+70.33% 163B
Average +1.61%+2.70%+28.46%+93.34% 370.02B
Weighted average by Cap. +1.37%+1.96%+42.23%+81.75%

Financials

2026 *2027 *
Net sales 68.81B 247M 216M 199M 185M 352M 23.56B 357M 2.39B 928M 11.58B 929M 909M 39.91B 75.92B 273M 239M 219M 204M 388M 26B 394M 2.63B 1.02B 12.78B 1.02B 1B 44.04B
Net income 10.49B 37.73M 32.98M 30.31M 28.25M 53.58M 3.59B 54.4M 364M 141M 1.77B 142M 139M 6.08B 12.42B 44.67M 39.05M 35.89M 33.45M 63.45M 4.25B 64.41M 431M 167M 2.09B 168M 164M 7.2B
Net Debt - -
Logo GlaxoSmithKline Pakistan Limited
GlaxoSmithKline Pakistan Limited is a Pakistan-based global biopharma company. The Company is engaged in the manufacturing and marketing of research-based specialties and pharmaceutical products. It caters to therapy areas, such as anti-infectives, dermatology, respiratory, analgesics, urology, and vaccines. Its pharmaceutical brands include Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol and Ventolin. Its portfolio has three product areas: vaccines, specialty, and general medicines. Its Amoxil branded products are an antibiotic indicated for the treatment of upper respiratory tract infections and helicobacter pylori. Its Vates portfolio comprises brands, such as Dermovate, Clobevate, Cutivate, and Betnovate. Its Vates portfolio addresses to a broad category of steroid responsive dermatoses indications, contact, and other kinds of dermatitis. Its Calpol branded products are used for treatment of mild to moderate fever and pain.
Employees
1,606
Date Price Change Volume
03/07/26 PKR 387.01 +2.66% 740,176
02/07/26 PKR 376.99 +0.23% 649,622
01/07/26 PKR 376.11 +1.58% 503,092
30/06/26 PKR 370.25 +1.66% 396,486
29/06/26 PKR 364.22 -0.73% 309,601
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
387.01PKR
Average target price
517.50PKR
Spread / Average Target
+33.72%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock